Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19098788 | 0.81 | LMNA (0.54) | KMT2AMEN1LMNATSHRSMN1; SMN2 | |
| SCHEMBL27497366 | 0.79 | ADORA2A (0.38) | LMNATSHRSMN1; SMN2POLBRAB9A | |
| SCHEMBL976056 | 0.79 | GAA (0.50) | SMN1; SMN2POLBRAB9AGAAMAPT | |
| SCHEMBL2214484 | 0.79 | LMNA (0.41) | KMT2AMEN1LMNATSHRSMN1; SMN2 | |
| SCHEMBL31460344 | 0.79 | KDM4E (0.39) | KMT2AMEN1LMNATSHRSMN1; SMN2 | |
| SCHEMBL646704 | 0.78 | ATM (0.36) | LMNATSHRSMN1; SMN2POLBRAB9A | |
| SCHEMBL166426 | 0.78 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2RAB9AGAANPC1 | |
| SCHEMBL3251664 | 0.76 | GAA (0.34) | LMNATSHRSMN1; SMN2POLBRAB9A | |
| SCHEMBL2353374 | 0.76 | GAA (0.37) | LMNATSHRSMN1; SMN2POLBRAB9A | |
| SCHEMBL645271 | 0.76 | ATM (0.35) | LMNATSHRSMN1; SMN2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | KMT2A 3597/4885MEN1 851/4885LMNA 182/4885 |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | KMT2A 3756/4885MEN1 863/4885LMNA 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.